The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Provided is a photosensitive resin composition including a reactive unsaturated compound, an alkali soluble resin, an initiator, and a pigment. The reactive unsaturated compound is selected to cause the composition to exhibit high-resolution pattern properties that facilitate forming a pixel defining film in a display device. The reactive unsaturated compound may be an acryl-based compound having at least three ethylenically unsaturated double bond groups in molecules and having a viscosity of about 200 mPa s to about 280 mPa s at 40? C. A display device including such pixel defining film is also presented.

Provided is a photosensitive resin composition including a reactive unsaturated compound, an alkali soluble resin, an initiator, and a pigment. The reactive unsaturated compound is selected to cause the composition to exhibit high-resolution pattern properties that facilitate forming a pixel defining film in a display device. The reactive unsaturated compound may be an acryl-based compound having at least three ethylenically unsaturated double bond groups in molecules and having a viscosity of about 200 mPa s to about 280 mPa s at 40? C. A display device including such pixel defining film is also presented.

The invention relates to lipid compounds of formula f(1) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R.sup.1 is either a C.sub.9 to C.sub.22 alkyl group, or a C.sub.9 to C.sub.22 alkenyl group having from 1 to 6 double bonds; R.sup.2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R.sup.3 is a hydrogen atom, or a group R.sup.2; R.sup.4 is a carboxylic acid or a derivative thereof; and X is methylene (CH.sub.2), or an oxygen or sulfur atom).

The invention relates to lipid compounds of formula f(1) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R.sup.1 is either a C.sub.9 to C.sub.22 alkyl group, or a C.sub.9 to C.sub.22 alkenyl group having from 1 to 6 double bonds; R.sup.2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R.sup.3 is a hydrogen atom, or a group R.sup.2; R.sup.4 is a carboxylic acid or a derivative thereof; and X is methylene (CH.sub.2), or an oxygen or sulfur atom).

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

The processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells comprise removing water from the cell fermentation broth or lysed cell composition before demulsification is conducted. Such a process has the benefits of reduced demulsification time and reduced salt use. Microbial oil comprising one or more PUFAs can be recovered from microbial cells by the process.

The processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells comprise removing water from the cell fermentation broth or lysed cell composition before demulsification is conducted. Such a process has the benefits of reduced demulsification time and reduced salt use. Microbial oil comprising one or more PUFAs can be recovered from microbial cells by the process.